Status:
COMPLETED
Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Myeloma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Donor mobilization : Donor will be mobilized with G-CSF (Granocyte) sub-cutaneous 10 µg/kg/day during 5 to 6 days. Hematopoïetic Stem Cell Harvest: By 1, 2, or 3 aphaeresis, a number of 4 x 106 cel...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Major patients not under guardianship
- Myeloma with high b2 microglobulin level (\> 3 mg/l) and/or chromosome 13 deletion, and/or translocation t(4;14) stage I DS with high evolutive potential or stage II, III DS.
- AND
- With response \>= 50% and \<= 90% after the first AutoHSCT (IFM 2005 01). The evaluation must be performed within 2 months after the first AutoHSCT.
- with an HLA identical related or unrelated donor ( match 10/10).
- Donor and recipient must have signed a written informed consent.
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00466674
Start Date
January 1 2007
End Date
September 1 2013
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohamad Sobh
Lyon, France, 69437